Список литературы
1. Выренков Ю.Е., Есипов А.В., Мусаилов В.А., Москаленко В.В., Шишло В.К., Поваляев А.В. Применение монооксида азота в хирургической практике. Физиотерапия, бальнеология и реабилитация. - 2014; 1:33-40.
2. Дарвин В.В., Земляной В.П., Мальцев П.А. Лечение гнойных ран челюстно-лицевой области с использованием монооксида азота. Раны и раневая инфекция. - 2007; 102-5.
3. Кабисов Р.К., Соколов В.В., Шехтер А.Б. и др. Первый опыт применения экзогенной NO-терапии для лечения послеоперационных ран и лучевых реакций у онкологических больных. // Рос. онкол. журн. - 2000; 1: 24-9.
4. Кабисов Р.К., Шехтер А.Б., Пекшев А.В. и др. Роль экзогенной NO-терапии в системе комплексного лечения ран и раневой патологии у онкологических больных. // Рос. онкол. журн. - 2000; 4: 16-22.
5. Решетов И.В., Кабисов Р.К., Шехтер А.Б., Пекшев А.В., Манейлова М.В. Применение воздушно-плазменного аппарата “Плазон” в режимах коагуляции и NO-терапии при реконструктивно-пластических операциях у онкологических больных // Анналы пласт., реконструктив. и эстет. хирургии. - 2000; 4: 24-39.
6. Тарасенко С.В., Дробышев А.Ю., Шипкова Т.П., Жукова H.A. и др. Тактика лечения больных с бисфосфонатным остеонекрозом челюстей. // Рос. стоматология. - 2012; 2: 3-13.
7. Шехтер А.Б., Кабисов Р.К., Пекшев А.В. и др. Экспериментально-клиническое обоснование плазмодинамической терапии ран оксидом азота. // Бюлл. эксперим. биол. и мед. - 1998; 126 (8): 210-15.
8. Khan A.A., Morrison A., Hanley D.A., Felsenberg D., McCauley L.K., O’Ryan F. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J. Bone Miner. Res. 2015; Jan.30(1): 3-23. doi: 10.1002/jbmr.2405.
9. Marx R.E. Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Oral. Maxillofac. Surg. 2003; 61: 1115-17.
10. Nicolatou-Galitis O., Papadopoulou E., Sarri T. et al. Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 2011; 112: 195-202.
11. Pozzi S, Marcheselli R, Sacchi S. et al. Analysis of frequency and risk factors for developing bisphosphonate associated necrosis of the jaw. American Society of Hematology Annual Meeting [abstract] Blood. 2005; 106: 5057.
12. Ruggiero S.L., Dodson T.B., Fantasia J., Goodday R., Aghaloo T., Mehrotra B. et al. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J. Oral. Maxillofac. Surg. 2014; Oct. 72(10): 1938-56.
13. Sharma D., Ivanovski S., Slevin M. et al. Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect. Vasc. Cell. 2013; 5: 1-5.
14. Tennis P., Rothman K.J., Bohn R.L., Tan H., Zavras A., Laskarides C. et al. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol. Drug. Saf. 2012; 21: 810-17.
REFERENCES:
1. Vy`renkov Yu.E., Esipov A.V., Musailov V.A., Moskalenko V.V., Shishlo V.K., Povalyaev A.V. The use of nitric oxide in surgical practice. Fizioterapiya, bal`neologiya i reabilitaciya. - 2014; 1:33-40. (in Russ.).
2. Darvin V.V., Zemlyanoj V.P., Mal`cev P.A. Treatment of purulent wounds of the maxillofacial region using nitrogen monoxide. Rany` i ranevaya infekciya. - 2007; 102-5. (in Russ.).
3. Kabisov R.K., Sokolov V.V., Shexter A.B. et al. The first experience of application of a exogenous NO-therapy for treating of postoperative wounds and beam reactions in oncologic patients. // Ros. onkol. zhurn. - 2000; 1: 24-9. (in Russ.).
4. Kabisov R.K., Shexter A.B., Pekshev A.V. et al. The role of exogenous NO-therapy in the system of complex treatment of wounds and wound pathology in cancer patients. // Ros. onkol. zhurn. - 2000; 4: 16-22. (in Russ.).
5. Reshetov I.V., Kabisov R.K., Shexter A.B., Pekshev A.V., Manejlova M.V. The application of air-plasma apparatus “Plason” in the regimes of coagulation and NO-therapy in plastic reconstructive surgery in cancer patients. // Annaly` plast., rekonstruktiv. i e`stet. xirurgii. - 2000; 4: 24-39. (in Russ.).
6. Tarasenko S.V., Drobyshev A.Yu., Shipkova T.P., Zhukova H.A. et al. The treatment of patients with bisphosphonate osteonecrosis of the jaw. // Ros. stomatologiya. - 2012; 2: 3-13. (in Russ.).
7. Shexter A.B., Kabisov R.K., Pekshev A.V. et al. Experimentally-clinical substantiation of the plasma-dynamic therapy of wounds with nitric oxide. // Byull. e`ksperim. biol. i med. - 1998; 126 (8): 210-15. (in Russ.).
8. Khan A.A., Morrison A., Hanley D.A., Felsenberg D., McCauley L.K., O’Ryan F. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J. Bone Miner. Res. 2015; Jan.30(1): 3-23. doi: 10.1002/jbmr.2405.
9. Marx R.E. Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Oral. Maxillofac. Surg. 2003; 61: 1115-17.
10. Nicolatou-Galitis O., Papadopoulou E., Sarri T. et al. Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 2011; 112: 195-202.
11. Pozzi S, Marcheselli R, Sacchi S. et al. Analysis of frequency and risk factors for developing bisphosphonate associated necrosis of the jaw. American Society of Hematology Annual Meeting [abstract] Blood. 2005; 106: 5057.
12. Ruggiero S.L., Dodson T.B., Fantasia J., Goodday R., Aghaloo T., Mehrotra B. et al. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J. Oral. Maxillofac. Surg. 2014; Oct. 72(10): 1938-56.
13. Sharma D., Ivanovski S., Slevin M. et al. Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect. Vasc. Cell. 2013; 5: 1-5.
14. Tennis P., Rothman K.J., Bohn R.L., Tan H., Zavras A., Laskarides C. et al. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol. Drug. Saf. 2012; 21: 810-17.